


VACCINATE AGAINST RSV

Respiratory Syncytial Virus (RSV)

Seasonal virus (fall to spring) that infects the nose, throat and lungs. More serious in young children and older adults. Causes cold-like symptoms but can lead to chest infections.



Older Adults

Recommended single lifetime dose

Abrysvo approved for those 60 years and older

Arexvy approved for those 50 years and older

Publicly funded for:

- All adults 75 years and older who have not received RSV.
- High risk adults 60-74
 - Receiving hemodialysis or peritoneal dialysis
 - Patients with glomerulonephritis who are moderately to severely immunocompromised.
 - Unhoused
 - First Nations, Indigenous, Inuit, or Metis

Benefits

- Reduce symptomatic RSV infections by 82% in first season
- Limited data on efficacy in those 80 years and up or those considered frail
- Uncertain evidence for the prevention of RSV related hospitalizations
- No evidence of efficacy for ICU admission prevention or deaths in adults 60 years and up